News

The three parties have entered into a binding agreement wherein Alexion has an exclusive option to acquire privately-held Prothelia and license Laminin-111 directly from the University of Nevada,

The company is utilizing its ProNutrein discovery platform to identify and develop protein pharmaconutrients, protein nutrients identified in food with beneficial impact in many areas of human health,

With the acquisition, Agenus will now be able to use 4-Antibody’ Retrocyte Display technology platform, which helps in the discovery and optimization of fully human antibodies against a

Under the deal, Clinipace will manage a major trial of PT20, a new iron-based phosphate binder, being developed for the treatment of hyperphosphataemia related to chronic kidney disease

Pyxant is a contract research laboratory specializing in GLP bioanalytical chemistry support for life sciences clients. Under the deal, Pyxant will offer bioanalytical method development, sample analysis and

Based on the review, the FDA has determined that they cannot approve the new drug application (NDA) in its present form, stating the NDA does have sufficient information

CTSI’s Catalyst Awards program solicits applications from university scientists who wish to move their translational research beyond the bench and into product development. The collaboration marks the first

Results of the study were recently published in Molecular Cancer Therapeutics. The study, led by Dr Arnon Nagler, director of the Hematology Division and Bone Marrow Transplantation Center

The product will be produced by Axxess Pharma’s wholly-owned subsidiary, AllStar Health Brands. Axxess Pharma president Dr Daniel Bagi noted the addition of Muscle Explosion expands the potential